S&CO Inc’s Blueprint Medicines BPMC Stock Holding History

S&CO Inc’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,000	Closed	-$1.54M	–	223
2025 Q2	$1.54M	Sell	12,000 -1,795	-13%	-$186K	0.1%	124
2025 Q1	$1.22M	Buy	13,795 +3,795	+38%	+$370K	0.08%	135
2024 Q4	$872K	Hold	10,000	–	–	0.06%	142
2024 Q3	$925K	Buy	10,000 +3,300	+49%	+$328K	0.06%	145
2024 Q2	$722K	Hold	6,700	–	–	0.05%	159
2024 Q1	$635K	Buy	+6,700	New	+$575K	0.04%	162

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

S&CO Inc's BPMC Position: Q3 2025 in Review

S&CO Inc sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 12,000 shares — an estimated $1.54M sold.

S&CO Inc first reported a position in BPMC in Q1 2024 and held it in 6 quarters. The position peaked at $1.54M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

S&CO Inc reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
S&CO Inc sold 12,000 Blueprint Medicines shares in Q3 2025, an estimated $1.54M.
S&CO Inc first reported a position in Blueprint Medicines in Q1 2024 and held it in 6 quarters.
S&CO Inc's Blueprint Medicines position peaked at $1.54M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on S&CO Inc's 13F filing for Q3 2025, filed 6 Nov 2025.